The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of sacituzumab govitecan for advanced esophageal squamous cell carcinoma patients (SG-ESCC).
 
Jhe-Cyuan Guo
Honoraria - Astellas Pharma; Bayer; Ipsen; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech
Consulting or Advisory Role - Astellas Pharma; Merck Serono; Ono Pharmaceutical
Travel, Accommodations, Expenses - Ipsen; MSD; Novartis; Ono Pharmaceutical
 
Tsung-Che Wu
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Janssen; Novartis; Roche
 
Ta-Chen Huang
No Relationships to Disclose
 
Hung-Yang Kuo
Stock and Other Ownership Interests - Daiichi Sankyo/UCB Japan
Speakers' Bureau - Merck; Ono Pharmaceutical
 
Chien-Huai Chuang
No Relationships to Disclose
 
Wei-Chen Lu
No Relationships to Disclose
 
Chia-Chi Lin
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche
Consulting or Advisory Role - Abbvie; Anbogen Therapeutics; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; IMPAC Medical Systems; Novartis; PharmaEngine
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; IMPAC Medical Systems; Lilly
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Gilead Sciences (Inst); Ipsen (Inst); Johnson & Johnson (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche